(GMAB) Genmab AS - Ratings and Ratios
Antibody, Cancer, Lymphoma, CancerTreatment, Medicines
GMAB EPS (Earnings per Share)
GMAB Revenue
Description: GMAB Genmab AS
Genmab A/S is a biotechnology company that specializes in developing antibody-based products for the treatment of cancer and other diseases. The company has a diverse pipeline of product candidates, including Epcoritamab, tisotumab vedotin, and Acasunlimab, among others, targeting various types of cancer, including lymphoma, cervical cancer, and solid tumors.
The companys product portfolio includes several marketed products, such as EPKINLY, TEPKINLY, Tivdak, DARZALEX/DARZALEX FASPRO, RYBREVANT, TECVAYLI, TALVEY, Kesimpta, and TEPEZZA, which are used to treat a range of conditions, including multiple myeloma, non-small cell lung cancer, and thyroid eye disease. Genmab A/S has a strong collaboration network with major pharmaceutical companies, including AbbVie, Pfizer, and Johnson & Johnson, which supports its research and development efforts.
From a financial perspective, Genmab A/S has a market capitalization of approximately $13.3 billion and a return on equity (ROE) of 25.61%, indicating a strong financial performance. Additional key performance indicators (KPIs) that can be used to evaluate the companys performance include revenue growth, research and development (R&D) expenditure as a percentage of revenue, and the number of product candidates in clinical trials. For instance, the companys revenue growth rate can be analyzed to assess its ability to generate sales from its marketed products. Furthermore, the companys R&D expenditure as a percentage of revenue can be evaluated to determine its commitment to innovation and product development.
Some other relevant KPIs for Genmab A/S include its cash and cash equivalents, total debt, and operating cash flow. The companys cash and cash equivalents can be used to assess its liquidity and ability to fund its operations, while its total debt can be evaluated to determine its financial leverage. Additionally, the companys operating cash flow can be analyzed to assess its ability to generate cash from its operations. By examining these KPIs, investors and analysts can gain a more comprehensive understanding of Genmab A/Ss financial performance and prospects.
GMAB Stock Overview
| Market Cap in USD | 16,656m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2009-06-01 |
GMAB Stock Ratings
| Growth Rating | -23.2% |
| Fundamental | 87.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -10.5% |
| Analyst Rating | 4.0 of 5 |
GMAB Dividends
Currently no dividends paidGMAB Growth Ratios
| Growth Correlation 3m | 88.9% |
| Growth Correlation 12m | -1.5% |
| Growth Correlation 5y | -75.5% |
| CAGR 5y | -6.77% |
| CAGR/Max DD 3y | -0.11 |
| CAGR/Mean DD 3y | -0.18 |
| Sharpe Ratio 12m | 1.48 |
| Alpha | 0.23 |
| Beta | 0.445 |
| Volatility | 32.25% |
| Current Volume | 1076.3k |
| Average Volume 20d | 1379.3k |
| Stop Loss | 27.3 (-3.3%) |
| Signal | 0.75 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (7.44b TTM) > 0 and > 6% of Revenue (6% = 1.37b TTM) |
| FCFTA 0.16 (>2.0%) and ΔFCFTA -0.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 91.29% (prev 92.65%; Δ -1.36pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 7.09b <= Net Income 7.44b (YES >=105%, WARN >=100%) |
| Net Debt (-7.27b) to EBITDA (7.66b) ratio: -0.95 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (619.9m) change vs 12m ago -4.46% (target <= -2.0% for YES) |
| Gross Margin 94.46% (prev 96.83%; Δ -2.37pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.24% (prev 49.11%; Δ 8.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 55.01 (EBITDA TTM 7.66b / Interest Expense TTM 134.0m) >= 6 (WARN >= 3) |
Altman Z'' 9.46
| (A) 0.51 = (Total Current Assets 24.78b - Total Current Liabilities 3.99b) / Total Assets 40.96b |
| (B) 0.56 = Retained Earnings (Balance) 22.80b / Total Assets 40.96b |
| (C) 0.19 = EBIT TTM 7.37b / Avg Total Assets 39.79b |
| (D) 2.92 = Book Value of Equity 21.53b / Total Liabilities 7.36b |
| Total Rating: 9.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 87.20
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.35% = 3.68 |
| 3. FCF Margin 29.32% = 7.33 |
| 4. Debt/Equity 0.10 = 2.49 |
| 5. Debt/Ebitda 0.45 = 2.34 |
| 6. ROIC - WACC (= 24.41)% = 12.50 |
| 7. RoE 21.90% = 1.82 |
| 8. Rev. Trend 63.59% = 4.77 |
| 9. EPS Trend 45.16% = 2.26 |
What is the price of GMAB shares?
Over the past week, the price has changed by +1.47%, over one month by +20.58%, over three months by +23.53% and over the past year by +6.25%.
Is Genmab AS a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GMAB is around 26.83 USD . This means that GMAB is currently overvalued and has a potential downside of -4.99%.
Is GMAB a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GMAB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.6 | 8.2% |
| Analysts Target Price | 30.6 | 8.2% |
| ValueRay Target Price | 29.7 | 5% |
Last update: 2025-09-05 04:44
GMAB Fundamental Data Overview
CCE Cash And Equivalents = 18.37b DKK (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.0311
P/E Forward = 21.1864
P/S = 4.5672
P/B = 3.0034
P/EG = 1.9654
Beta = 0.8
Revenue TTM = 22.78b DKK
EBIT TTM = 7.37b DKK
EBITDA TTM = 7.66b DKK
Long Term Debt = 3.38b DKK (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 101.4m DKK (from shortTermDebt, last quarter)
Debt = 3.48b DKK (Calculated: Short Term 101.4m + Long Term 3.38b)
Net Debt = -7.27b DKK (from netDebt column, last quarter)
Enterprise Value = 90.84b DKK (105.73b + Debt 3.48b - CCE 18.37b)
Interest Coverage Ratio = 55.01 (Ebit TTM 7.37b / Interest Expense TTM 134.0m)
FCF Yield = 7.35% (FCF TTM 6.68b / Enterprise Value 90.84b)
FCF Margin = 29.32% (FCF TTM 6.68b / Revenue TTM 22.78b)
Net Margin = 32.65% (Net Income TTM 7.44b / Revenue TTM 22.78b)
Gross Margin = 94.46% ((Revenue TTM 22.78b - Cost of Revenue TTM 1.26b) / Revenue TTM)
Tobins Q-Ratio = 4.22 (Enterprise Value 90.84b / Book Value Of Equity 21.53b)
Interest Expense / Debt = 1.64% (Interest Expense 57.0m / Debt 3.48b)
Taxrate = 14.40% (1.32b / 9.16b)
NOPAT = 6.31b (EBIT 7.37b * (1 - 14.40%))
Current Ratio = 6.22 (Total Current Assets 24.78b / Total Current Liabilities 3.99b)
Debt / Equity = 0.10 (Debt 3.48b / last Quarter total Stockholder Equity 33.60b)
Debt / EBITDA = 0.45 (Net Debt -7.27b / EBITDA 7.66b)
Debt / FCF = 0.52 (Debt 3.48b / FCF TTM 6.68b)
Total Stockholder Equity = 33.95b (last 4 quarters mean)
RoA = 18.15% (Net Income 7.44b, Total Assets 40.96b )
RoE = 21.90% (Net Income TTM 7.44b / Total Stockholder Equity 33.95b)
RoCE = 19.75% (Ebit 7.37b / (Equity 33.95b + L.T.Debt 3.38b))
RoIC = 31.87% (NOPAT 6.31b / Invested Capital 19.80b)
WACC = 7.45% (E(105.73b)/V(109.21b) * Re(7.65%)) + (D(3.48b)/V(109.21b) * Rd(1.64%) * (1-Tc(0.14)))
Shares Correlation 3-Years: -87.03 | Cagr: -0.56%
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈6.61b ; Y1≈8.16b ; Y5≈13.92b
Fair Price DCF = 384.9 (DCF Value 236.75b / Shares Outstanding 615.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 45.16 | EPS CAGR: 0.68% | SUE: 0.93 | # QB: 1
Revenue Correlation: 63.59 | Revenue CAGR: 14.01% | SUE: N/A | # QB: None
Additional Sources for GMAB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle